Канада - английский - Health Canada

marcan pharmaceuticals inc - oseltamivir (oseltamivir phosphate) - capsule - 30mg - oseltamivir (oseltamivir phosphate) 30mg - neuraminidase inhibitors

Канада - английский - Health Canada

marcan pharmaceuticals inc - oseltamivir (oseltamivir phosphate) - capsule - 45mg - oseltamivir (oseltamivir phosphate) 45mg - neuraminidase inhibitors

Канада - английский - Health Canada

marcan pharmaceuticals inc - oseltamivir (oseltamivir phosphate) - capsule - 75mg - oseltamivir (oseltamivir phosphate) 75mg - neuraminidase inhibitors

Канада - английский - Health Canada

angita pharma inc. - oseltamivir (oseltamivir phosphate) - capsule - 30mg - oseltamivir (oseltamivir phosphate) 30mg - neuraminidase inhibitors

Канада - английский - Health Canada

angita pharma inc. - oseltamivir (oseltamivir phosphate) - capsule - 45mg - oseltamivir (oseltamivir phosphate) 45mg - neuraminidase inhibitors

Канада - английский - Health Canada

angita pharma inc. - oseltamivir (oseltamivir phosphate) - capsule - 75mg - oseltamivir (oseltamivir phosphate) 75mg - neuraminidase inhibitors

Соединенные Штаты - английский - NLM (National Library of Medicine)

alvogen inc. - oseltamivir phosphate (unii: 4a3o49ngez) (oseltamivir acid - unii:k6106lv5q8) - oseltamivir carboxylate 30 mg - oseltamivir phosphate capsules are indicated for the treatment of acute, uncomplicated illness due to influenza a and b infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. oseltamivir phosphate capsules are indicated for the prophylaxis of influenza a and b in patients 1 year and older. - oseltamivir phosphate capsules are not a substitute for early influenza vaccination on an annual basis as recommended by the centers for disease control and prevention advisory committee on immunization practices. - influenza viruses change over time. emergence of resistance substitutions could decrease drug effectiveness. other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use oseltamivir phosphate capsules [see microbiology (12.4)]. -  oseltamivir phosphate capsules are not recom

Соединенные Штаты - английский - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - oseltamivir phosphate (unii: 4a3o49ngez) (oseltamivir acid - unii:k6106lv5q8) - oseltamivir carboxylate 6 mg in 1 ml - oseltamivir phosphate for oral suspension is indicated for the treatment of acute, uncomplicated illness due to influenza a and b infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. oseltamivir phosphate for oral suspension is indicated for the prophylaxis of influenza a and b in patients 1 year and older. - oseltamivir phosphate for oral suspension is not a substitute for early influenza vaccination on an annual basis as recommended by the centers for disease control and prevention advisory committee on immunization practices. - influenza viruses change over time. emergence of resistance substitutions could decrease drug effectiveness. other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use oseltamivir phosphate for oral

Соединенные Штаты - английский - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - oseltamivir phosphate (unii: 4a3o49ngez) (oseltamivir carboxylate - unii:k6106lv5q8) - oseltamivir carboxylate 75 mg - oseltamivir phosphate capsules, usp is indicated for the treatment of acute, uncomplicated illness due to influenza a and b infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. oseltamivir phosphate is indicated for the prophylaxis of influenza a and b in patients 1 year and older. - oseltamivir phosphate capsules is not a substitute for early influenza vaccination on an annual basis as recommended by the centers for disease control and prevention advisory committee on immunization practices. - influenza viruses change over time. emergence of resistance substitutions could decrease drug effectiveness. other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use oseltamivir phosphate capsules [see microbiology (12.4)]. -  oseltamivir phosphate capsules is not recommended f

Соединенные Штаты - английский - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - oseltamivir phosphate (unii: 4a3o49ngez) (oseltamivir acid - unii:k6106lv5q8) - oseltamivir carboxylate 30 mg - oseltamivir phosphate capsules, usp are indicated for the treatment of acute, uncomplicated illness due to influenza a and b infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. oseltamivir phosphate capsules, usp are indicated for the prophylaxis of influenza a and b in patients 1 year and older. - oseltamivir phosphate capsules, usp are not a substitute for early influenza vaccination on an annual basis as recommended by the centers for disease control and prevention advisory committee on immunization practices. - influenza viruses change over time. emergence of resistance substitutions could decrease drug effectiveness. other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use oseltamivir phosphate capsules, usp [see micr